Sylvain Bouix

ORCID: 0000-0003-1326-6054
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Advanced Neuroimaging Techniques and Applications
  • Functional Brain Connectivity Studies
  • Traumatic Brain Injury Research
  • Medical Image Segmentation Techniques
  • Advanced MRI Techniques and Applications
  • Fetal and Pediatric Neurological Disorders
  • Traumatic Brain Injury and Neurovascular Disturbances
  • Schizophrenia research and treatment
  • Morphological variations and asymmetry
  • Tensor decomposition and applications
  • MRI in cancer diagnosis
  • Medical Imaging Techniques and Applications
  • Congenital heart defects research
  • 3D Shape Modeling and Analysis
  • Image Retrieval and Classification Techniques
  • Color Science and Applications
  • Atomic and Subatomic Physics Research
  • Advanced Vision and Imaging
  • Cell Image Analysis Techniques
  • Medical Imaging and Analysis
  • Coronary Artery Anomalies
  • Psychosomatic Disorders and Their Treatments
  • Mental Health Research Topics
  • Cardiac Arrest and Resuscitation
  • Neuroscience and Music Perception

Harvard University
2016-2025

Brigham and Women's Hospital
2016-2025

École de Technologie Supérieure
2022-2025

Université du Québec à Montréal
2023-2025

New York University
2024

Boston University
2004-2024

Alzheimer's Association
2024

Cognitive Neuroimaging Lab
2007-2023

Landscape Research Group
2023

VA San Diego Healthcare System
2023

Sinéad Kelly Neda Jahanshad Andrew Zalesky Peter Kochunov Ingrid Agartz and 95 more Clara Alloza Ole A. Andreassen Celso Arango Nerisa Banaj Sylvain Bouix Chad A. Bousman Rachel M. Brouwer Jason Bruggemann Juan Bustillo Wiepke Cahn Vince D. Calhoun Dara M. Cannon Vaughan J. Carr Stanley V. Catts Jian Chen J. X. Chen X. Chen Chiara Chiapponi Kl K Cho Valentina Ciullo Aiden Corvin Benedicto Crespo‐Facorro Vanessa Cropley Pietro De Rossi Covadonga M. Díaz‐Caneja Erin W. Dickie Stefan Ehrlich F-m Fan Joshua Faskowitz Helena Fatouros‐Bergman Lena Flyckt Judith M. Ford J-P Fouche Masaki Fukunaga Michael Gill David C. Glahn Randy L. Gollub Esther Goudzwaard Hua Guo Raquel E. Gur Ruben C. Gur Tiril P. Gurholt Ryota Hashimoto Sean N. Hatton Frans Henskens Derrek P. Hibar Ian B. Hickie L. Elliot Hong Jiřı́ Horáček Fleur M. Howells Hilleke E. Hulshoff Pol Craig Hyde Dmitry Isaev Assen Jablensky Philip R. Jansen Joost Janssen Erik G. Jönsson Leah Jung René S. Kahn Zora Kikinis K Liu Paul Klauser Christian Knöchel Marek Kubicki Jim Lagopoulos C. D. de LANGEN Stephen M. Lawrie Rhoshel Lenroot Kelvin O. Lim Carlos López‐Jaramillo Amanda E. Lyall Vincent A. Magnotta René C.W. Mandl Daniel H. Mathalon Robert W. McCarley Simon McCarthy‐Jones Colm McDonald Sarah McEwen Andrew M. McIntosh Tomáš Melicher R I Mesholam-Gately Patricia T. Michie Bryan Mowry Bryon A. Mueller Dominick T. Newell Patricio O’Donnell Viola Oertel‐Knöchel Lena Oestreich Sara A. Paciga Christos Pantelis Ofer Pasternak Godfrey D. Pearlson Gaia Romana Pellicano A Pereira J.-P. Restrepo Zapata

The regional distribution of white matter (WM) abnormalities in schizophrenia remains poorly understood, and reported disease effects on the brain vary widely between studies. In an effort to identify commonalities across studies, we perform what believe is first ever large-scale coordinated study WM microstructural differences schizophrenia. Our analysis consisted 2359 healthy controls 1963 patients from 29 independent international studies; harmonized processing statistical analyses...

10.1038/mp.2017.170 article EN cc-by Molecular Psychiatry 2017-10-17

Diffusion MRI has been successful in identifying the existence of white matter abnormalities schizophrenia vivo. However, role these etiology is not well understood. Accumulating evidence from imaging, histological, genetic, and immunochemical studies support involvement axonal degeneration neuroinflammation--ubiquitous components neurodegenerative disorders--as underlying pathologies abnormalities. Nevertheless, current imaging modalities cannot distinguish neuroinflammation degeneration,...

10.1523/jneurosci.2904-12.2012 article EN cc-by-nc-sa Journal of Neuroscience 2012-11-28
Cassandra Wannan Barnaby Nelson Jean Addington Kelly Allott Alan Anticevic and 95 more Celso Arango Justin T. Baker Carrie E. Bearden Tashrif Billah Sylvain Bouix Matthew R. Broome Kate Buccilli Kristin S. Cadenhead Monica E. Calkins Tyrone D. Cannon Guillermo Cecci Eric Chen Kang Ik K. Cho Jimmy Choi Scott Clark Michael Coleman Philippe Conus Cheryl M. Corcoran Barbara A. Cornblatt Covadonga M. Díaz‐Caneja Dominic Dwyer Bjørn H. Ebdrup Lauren M. Ellman Paolo Fusar‐Poli Liliana Galindo Pablo A. Gaspar Carla Gerber Louise Birkedal Glenthøj Robert J. Glynn Michael P. Harms Leslie E. Horton René S. Kahn Joseph Kambeitz Lana Kambeitz‐Ilankovic John M. Kane Tina Kapur Matcheri S. Keshavan Sung‐Wan Kim Nikolaos Koutsouleris Marek Kubicki Jun Soo Kwon Kerstin Langbein Kathryn E. Lewandowski Gregory A. Light Daniel Mamah Patricia Marcy Daniel H. Mathalon Patrick D. McGorry Vijay A. Mittal Merete Nordentoft Ángela Núñez Ofer Pasternak Godfrey D. Pearlson Jesús Pérez Diana O. Perkins Albert R. Powers David R. Roalf Fred W. Sabb Jason Schiffman Jai Shah Stefan Smesny Jessica Spark William S. Stone Gregory P. Strauss Zailyn Tamayo John Torous Rachel Upthegrove Márk Vangel Swapna Verma Jijun Wang Inge Winter-van Rossum Daniel H. Wolf Phillip Wolff Stephen J. Wood Alison R. Yung Carla Agurto Mario Álvarez‐Jiménez G. Paul Amminger Marco Armando Ameneh Asgari-Targhi John D. Cahill Ricardo E. Carrión Eduardo Castro Suheyla Cetin‐Karayumak M. Mallar Chakravarty Youngsun Cho David Cotter Simon D’Alfonso Michaela Ennis Shreyas Fadnavis Clara Fonteneau Caroline X. Gao Tina Gupta Raquel E. Gur Ruben C. Gur

Abstract This article describes the rationale, aims, and methodology of Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ). is largest international collaboration to date that will develop algorithms predict trajectories outcomes individuals at clinical high risk (CHR) for psychosis advance development use novel pharmacological interventions CHR individuals. We present a description participating research networks data processing analysis coordination center, their processes...

10.1093/schbul/sbae011 article EN cc-by Schizophrenia Bulletin 2024-03-07

Clinical ascertainment and clinical outcome are key features of any large multisite study. In the ProNET PRESCIENT research networks, Accelerating Medicines Partnership® Schizophrenia (AMP®SCZ) Ascertainment Outcome Measures Team aimed to establish a harmonized assessment protocol across these two networks define criteria primary secondary endpoints. addition developing protocol, goals this aspect AMP SCZ project were: (1) implement monitor training, participants, assessments; (2) provide...

10.1038/s41537-025-00556-7 article EN cc-by-nc-nd Schizophrenia 2025-04-03
Kelly Allott Walid Yassin Luis Alameda Tashrif Billah Owen Borders and 92 more Kate Buccilli Ricardo E. Carrión Rolando I. Castillo-Passi Kang Ik K. Cho Kristyn Chin Michael J. Coleman Beau‐Luke Colton Sebastián Corral Dominic Dwyer Kristina Ballestad Gundersen Ruben C. Gur Gil D. Hoftman Grace Jacobs Sinéad Kelly Kathryn E. Lewandowski Patricia Marcy Priya Matneja Danielle McLaughlin Ángela Núñez Setari Parsa Nora Penzel Susan Ray Jenna Reinen Kosha Ruparel Michael Sand G Santorelli Johanna Seitz‐Holland Jessica Spark Zailyn Tamayo Alan J. Thompson Sophie Tod Cassandra Wannan Alana Wickham Stephen J. Wood Eirini Zoupou Jean Addington Alan Anticevic Celso Arango Nicholas J K Breitborde Matthew R. Broome Kristin S. Cadenhead Monica E. Calkins Eric Chen Jimmy Choi Philippe Conus Cheryl M. Corcoran Barbara A. Cornblatt Lauren M. Ellman Paolo Fusar‐Poli Pablo A. Gaspar Carla Gerber Louise Birkedal Glenthøj Leslie E. Horton Christy Lai Ming Hui Joseph Kambeitz Lana Kambeitz‐Ilankovic Matcheri S. Keshavan Sung‐Wan Kim Nikolaos Koutsouleris Jun Soo Kwon Kerstin Langbein Daniel Mamah Covadonga M. Díaz‐Caneja Daniel H. Mathalon Vijay A. Mittal Merete Nordentoft Godfrey D. Pearlson Diana O. Perkins Jesús Pérez Albert R. Powers Jack C. Rogers Fred W. Sabb Jason Schiffman Jai Shah Steven M. Silverstein Stefan Smesny Gregory P. Strauss Judy Thompson Rachel Upthegrove Swapna Verma Jijun Wang Daniel H. Wolf Ofer Pasternak Sylvain Bouix Patrick D. McGorry John M. Kane René S. Kahn Carrie E. Bearden Martha E. Shenton Scott W. Woods Barnaby Nelson William S. Stone

Cognitive impairment occurs at higher rates in individuals clinical high risk (CHR) for psychosis relative to healthy peers, and it contributes unique variance multivariate prediction models of transition psychosis. Such is considered a core biomarker schizophrenia. Thus, cognition key domain measured the Accelerating Medicines Partnership® program Schizophrenia (AMP SCZ initiative). The aim this paper describe rationale, processes, considerations, final harmonization cognitive battery used...

10.1038/s41537-025-00578-1 article EN cc-by-nc-nd Schizophrenia 2025-03-24

Abstract Neuroimaging with MRI has been a frequent component of studies individuals at clinical high risk (CHR) for developing psychosis, goals understanding potential brain regions and systems impacted in the CHR state identifying prognostic or predictive biomarkers that can enhance our ability to forecast outcomes. To date, most involving are likely not sufficiently powered generate robust generalizable neuroimaging results. Here, we describe prospective, advanced, modern protocol was...

10.1038/s41537-025-00581-6 article EN cc-by Schizophrenia 2025-04-02

Abstract Modern research management, particularly for publicly funded studies, assumes a data governance model in which grantees are considered stewards rather than owners of important sets. Thus, there is an expectation that collected shared as widely possible with the general community. This presents problems complex studies involve sensitive health information. The latter requires balancing participant privacy needs Here, we report on operation ecosystem crafted Accelerating Medicines...

10.1038/s41537-025-00560-x article EN cc-by Schizophrenia 2025-04-03

10.1023/a:1016376116653 article EN International Journal of Computer Vision 2002-01-01

10.1016/j.media.2004.06.026 article EN Medical Image Analysis 2004-10-21

Youth football players may incur hundreds of repetitive head impacts (RHI) in one season. Our recent research suggests that exposure to RHI during a critical neurodevelopmental period prior age 12 lead greater later-life mood, behavioral, and cognitive impairments. Here, we examine the relationship between first (AFE) through tackle corpus callosum (CC) microstructure using magnetic resonance diffusion tensor imaging (DTI). Forty retired National Football League (NFL) players, ages 40-65,...

10.1089/neu.2014.3822 article EN Journal of Neurotrauma 2015-07-22

In healthy adult individuals, late life is a dynamic time of change with respect to the microstructural integrity white matter tracts. Yet, elderly individuals are generally excluded from diffusion tensor imaging studies in schizophrenia. Therefore, we examined frontotemporal and interhemispheric tracts schizophrenia across lifespan. Diffusion data 25 younger schizophrenic patients (≤55 years), controls, older (≥56 years) controls were analysed. Patients each group individually matched...

10.1093/brain/awq040 article EN Brain 2010-03-17

Background Patients with schizophrenia (SZ) characteristically exhibit supranormal levels of cortical activity to self-induced sensory stimuli, ostensibly because abnormalities in the neural signals (corollary discharges, CDs) normatively involved suppressing consequences self-generated actions. The nature these is unknown. This study investigated whether SZ patients experience CDs that are abnormally delayed their arrival at cortex. Method Twenty-one and 25 matched control participants...

10.1017/s0033291710001376 article EN Psychological Medicine 2010-07-22

A significant percentage of individuals diagnosed with mild traumatic brain injury (mTBI) experience persistent post-concussive symptoms (PPCS). Little is known about the pathology these and there often no radiological evidence based on conventional clinical imaging. We aimed to utilize methods evaluate microstructural tissue changes determine whether or not a link PPCS was present. novel analysis method developed identify abnormalities in high-resolution diffusion tensor imaging (DTI) when...

10.1371/journal.pone.0066205 article EN cc-by PLoS ONE 2013-06-11

Abstract Brain morphology differs markedly between individuals with schizophrenia, but the cellular and genetic basis of this heterogeneity is poorly understood. Here, we sought to determine whether cortical thickness (CTh) in schizophrenia relates interregional variation distinct neural cell types, as inferred from established gene expression data person-specific genomic variation. This study comprised 1849 participants total, including a discovery (140 cases 1267 controls) validation...

10.1038/s41380-022-01460-7 article EN cc-by Molecular Psychiatry 2022-02-10

Abstract Aim To harmonize two ascertainment and severity rating instruments commonly used for the clinical high risk syndrome psychosis (CHR‐P): Structured Interview Psychosis‐risk Syndromes (SIPS) Comprehensive Assessment of At‐Risk Mental States (CAARMS). Methods The initial workshop is described in companion report from Addington et al. After workshop, lead experts each instrument continued harmonizing attenuated positive symptoms criteria CHR‐P through an intensive series joint...

10.1111/eip.13457 article EN cc-by Early Intervention in Psychiatry 2023-08-28

The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) project assesses a large sample of individuals at clinical high-risk for developing psychosis (CHR) and community controls. Subjects are enrolled in 43 sites across 5 continents. assessments include domains similar to those acquired previous CHR studies along with novel that collected longitudinally period 2 years. In parallel the data acquisition, multidisciplinary teams experts have been working formulate analysis strategy...

10.1038/s41537-025-00561-w article EN cc-by-nc-nd Schizophrenia 2025-04-03
Coming Soon ...